TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Flow Biphasic NCPAP Versus Infant Flow NCPAP for the Facilitation of Successful Extubation in Infants </= 1250 Grams: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare two methods of delivering Nasal Continuous Airway Pressure (NCPAP): Biphasic Mode and a continuous mode, to see which is better in getting babies off the ventilator and decreasing lung damage.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Biphasic Infant flow NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP | Intervention Type: PROCEDURE; Name: Biphasic Infant flow NCPAP; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): 2
C: Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nasal intermittent positive pressure ventilation | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: nasal intermittent positive pressure ventilation | Intervention Type: DEVICE; Name: nasal intermittent positive pressure ventilation; Assigned to Arm(s): NCPAP, NIPPV
D: Arm Label: NAVA-PS; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Arm Label: PS-NAVA; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Intervention Type: DEVICE; Name: noninvasive respiratory support with NAVA mode and PSV; Assigned to Arm(s): NAVA-PS, PS-NAVA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomised Study to Examine the Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy
Brief Summary: Disease management using a multidisciplinary team to achieve and maintain optimal metabolic and cardiovascular risk factors control in Type 2 diabetic patients with nephropathy reduces the incidence of end stage renal disease (ESRD) and improves clinical outcomes compared to usual clinic-based care


Options:
A: Arm Label: TEAMcare treatment of diabetes; Type: ACTIVE_COMPARATOR; Interventions: Other: TEAMcare treatment of diabetes | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: TEAMcare treatment of diabetes; Assigned to Arm(s): TEAMcare treatment of diabetes
B: Arm Label: DH-4; Type: ACTIVE_COMPARATOR; Interventions: Other: Proteus Discover | Arm Label: DH-12; Type: ACTIVE_COMPARATOR; Interventions: Other: Proteus Discover | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Proteus Discover; Assigned to Arm(s): DH-12, DH-4 | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Intervention Type: BEHAVIORAL; Name: Multidisciplinary team care; Assigned to Arm(s): N/A
D: Arm Label: Technology-based self-management model; Type: EXPERIMENTAL; Interventions: Device: Technology-based self-management model | Arm Label: Conventional self-management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Technology-based self-management model; Assigned to Arm(s): Technology-based self-management model

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Observer-blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years
Brief Summary: The main aim of this vaccine is to prevent cervical cancer in women. However, it could also be relevant to vaccinate selected groups of males. Therefore, this study is designed to evaluate the safety and immunogenicity of the HPV vaccine in pre-teen and adolescent male subjects aged 10-18 years.


Options:
A: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1/AS04; Assigned to Arm(s): N/A
B: Arm Label: Cervarix-12 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix TM | Arm Label: Cervarix-6 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Cervarix-12 Group | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Cervarix-6 Group
C: Arm Label: 3-dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2 doses by default; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Single-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Unvaccinated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®); Assigned to Arm(s): 2 doses by default, 2-dose, 3-dose, Single-dose
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Observer-blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years
Brief Summary: The main aim of this vaccine is to prevent cervical cancer in women. However, it could also be relevant to vaccinate selected groups of males. Therefore, this study is designed to evaluate the safety and immunogenicity of the HPV vaccine in pre-teen and adolescent male subjects aged 10-18 years.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 vaccine (Cervarix™) | Arm Label: Aimmugen Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Aimmugen™ | Intervention Type: BIOLOGICAL; Name: HPV-16/18 vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Aimmugen™; Assigned to Arm(s): Aimmugen Group
C: Arm Label: Gardasil®; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Arm Label: Cervarix®; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil® | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix®
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Care: Smoking Reduction to Aid Cessation; Part of Hatsukami's Tobacco Exposure Reduction
Brief Summary: The purpose of this study is to determine whether an extended care treatment model lasting over a year will increase long-term smoking cessation rates compared to the standard 8 week treatment of care.


Options:
A: Arm Label: Web + Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Web + Phone | Arm Label: Web Only; Type: EXPERIMENTAL; Interventions: Behavioral: Web Only | Arm Label: Phone Only; Type: EXPERIMENTAL; Interventions: Behavioral: Phone Only | Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Web + Phone; Assigned to Arm(s): Web + Phone | Intervention Type: BEHAVIORAL; Name: Web Only; Assigned to Arm(s): Web Only | Intervention Type: BEHAVIORAL; Name: Phone Only; Assigned to Arm(s): Phone Only | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Control
B: Arm Label: Longitudinal Care; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation | Intervention Type: BEHAVIORAL; Name: smoking cessation; Assigned to Arm(s): Longitudinal Care, Usual Care
C: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C
D: Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Nicotine Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Brief Hospital Counseling | Arm Label: Telephone Counseling + Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Brief hospital counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Hospital Counseling | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Patches, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Brief Hospital Counseling; Assigned to Arm(s): Brief hospital counseling, Nicotine Patches, Telephone Counseling, Telephone Counseling + Patches

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Care: Smoking Reduction to Aid Cessation; Part of Hatsukami's Tobacco Exposure Reduction
Brief Summary: The purpose of this study is to determine whether an extended care treatment model lasting over a year will increase long-term smoking cessation rates compared to the standard 8 week treatment of care.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Longitudinal Care; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation | Intervention Type: BEHAVIORAL; Name: smoking cessation; Assigned to Arm(s): Longitudinal Care, Usual Care
C: Arm Label: WhatsApp; Type: EXPERIMENTAL; Interventions: Behavioral: WhatsApp | Arm Label: Facebook; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WhatsApp; Assigned to Arm(s): WhatsApp | Intervention Type: BEHAVIORAL; Name: Facebook; Assigned to Arm(s): Facebook
D: Arm Label: virtual reality exposure therapy (VRET); Type: EXPERIMENTAL; Interventions: Other: virtual reality exposure treatment | Arm Label: cognitive and behavioral approaches therapy without VRET; Type: EXPERIMENTAL; Interventions: Other: cognitive and behavioral approaches therapy | Intervention Type: OTHER; Name: virtual reality exposure treatment; Assigned to Arm(s): virtual reality exposure therapy (VRET) | Intervention Type: OTHER; Name: cognitive and behavioral approaches therapy; Assigned to Arm(s): cognitive and behavioral approaches therapy without VRET

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Care: Smoking Reduction to Aid Cessation; Part of Hatsukami's Tobacco Exposure Reduction
Brief Summary: The purpose of this study is to determine whether an extended care treatment model lasting over a year will increase long-term smoking cessation rates compared to the standard 8 week treatment of care.


Options:
A: Arm Label: Ban & Informational Pamphlet; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Use Ban, Behavioral: Informational Pamphlet | Arm Label: Ban & Tailored Pamphlet; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Use Ban, Behavioral: Tailored Pamphlet | Arm Label: Ban & Tailored Pamphlet & Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Use Ban, Behavioral: Tailored Pamphlet, Behavioral: Relapse Prevention Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Use Ban; Assigned to Arm(s): Ban & Informational Pamphlet, Ban & Tailored Pamphlet, Ban & Tailored Pamphlet & Intervention | Intervention Type: BEHAVIORAL; Name: Tailored Pamphlet; Assigned to Arm(s): Ban & Tailored Pamphlet, Ban & Tailored Pamphlet & Intervention | Intervention Type: BEHAVIORAL; Name: Informational Pamphlet; Assigned to Arm(s): Ban & Informational Pamphlet | Intervention Type: BEHAVIORAL; Name: Relapse Prevention Intervention; Assigned to Arm(s): Ban & Tailored Pamphlet & Intervention
B: Arm Label: Longitudinal Care; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation | Intervention Type: BEHAVIORAL; Name: smoking cessation; Assigned to Arm(s): Longitudinal Care, Usual Care
C: Arm Label: QUIT4Ever; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy, Other: Smoking cessation counseling, Behavioral: mobile contingency management, Other: Stay Quit Coach | Arm Label: Control Contact Condition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy, Other: Smoking cessation counseling, Behavioral: mobile contingency management | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: OTHER; Name: Smoking cessation counseling; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: BEHAVIORAL; Name: mobile contingency management; Assigned to Arm(s): Control Contact Condition, QUIT4Ever | Intervention Type: OTHER; Name: Stay Quit Coach; Assigned to Arm(s): QUIT4Ever
D: Arm Label: Receiving WhatsApp messages; Type: EXPERIMENTAL; Interventions: Behavioral: WhatsApp embedded in smoking cessation service | Arm Label: Not receiving WhatsApp messages; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WhatsApp embedded in smoking cessation service; Assigned to Arm(s): Receiving WhatsApp messages

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Usual Care Versus Specialized, Phase-specific Care in the Public Sector for First Episode Psychosis.
Brief Summary: The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis. The pharmacologic and psychosocial treatments will be delivered within a state public mental health center.


Options:
A: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
B: Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as Usual in the community | Arm Label: STEP Care; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Behavioral: Cognitive remediation, Drug: Medications, Behavioral: MFG, Behavioral: Assertive case management | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): STEP Care | Intervention Type: BEHAVIORAL; Name: Cognitive remediation; Assigned to Arm(s): STEP Care | Intervention Type: DRUG; Name: Medications; Assigned to Arm(s): STEP Care | Intervention Type: BEHAVIORAL; Name: MFG; Assigned to Arm(s): STEP Care | Intervention Type: BEHAVIORAL; Name: Assertive case management; Assigned to Arm(s): STEP Care | Intervention Type: OTHER; Name: Treatment as Usual in the community; Assigned to Arm(s): Treatment as usual
C: Arm Label: Individual psychoeducation; Type: EXPERIMENTAL; Interventions: Other: Individual psychoeducation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Individual psychoeducation; Assigned to Arm(s): Individual psychoeducation
D: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Usual Care Versus Specialized, Phase-specific Care in the Public Sector for First Episode Psychosis.
Brief Summary: The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis. The pharmacologic and psychosocial treatments will be delivered within a state public mental health center.


Options:
A: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
B: Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as Usual in the community | Arm Label: STEP Care; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Behavioral: Cognitive remediation, Drug: Medications, Behavioral: MFG, Behavioral: Assertive case management | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): STEP Care | Intervention Type: BEHAVIORAL; Name: Cognitive remediation; Assigned to Arm(s): STEP Care | Intervention Type: DRUG; Name: Medications; Assigned to Arm(s): STEP Care | Intervention Type: BEHAVIORAL; Name: MFG; Assigned to Arm(s): STEP Care | Intervention Type: BEHAVIORAL; Name: Assertive case management; Assigned to Arm(s): STEP Care | Intervention Type: OTHER; Name: Treatment as Usual in the community; Assigned to Arm(s): Treatment as usual
C: Arm Label: Treatment As Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment As Usual (TAU) | Arm Label: TAU+CBT for pts+Family Intervention+CM; Type: EXPERIMENTAL; Interventions: Behavioral: TAU+CBT for pts+Family Intervention+CM. | Intervention Type: OTHER; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: TAU+CBT for pts+Family Intervention+CM.; Assigned to Arm(s): TAU+CBT for pts+Family Intervention+CM
D: Arm Label: 5 year; Type: EXPERIMENTAL; Interventions: Behavioral: OPUS 5 years | Arm Label: 2 years of OPUS treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 years OPUS treatment | Intervention Type: BEHAVIORAL; Name: 2 years OPUS treatment; Assigned to Arm(s): 2 years of OPUS treatment | Intervention Type: BEHAVIORAL; Name: OPUS 5 years; Assigned to Arm(s): 5 year

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease
Brief Summary: The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin in patients with risk factors for heart disease.


Options:
A: Arm Label: Pitavastatin 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Arm Label: Pitavastatin 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Arm Label: Pitavastatin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 1 mg, Pitavastatin 2 mg, Pitavastatin 4 mg | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin 10 mg, Pravastatin 20 mg, Pravastatin 40 mg
B: Arm Label: Pitavastatin 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Arm Label: Pitavastatin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 2 mg, Pitavastatin 4 mg | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Simvastatin 20 mg, Simvastatin 40 mg
C: Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): N/A
D: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: pitavastatin | Arm Label: Simvastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): Simvastatin 40 mg QD

Answer: D